AR111233A1 - Inhibidores de tyk2, usos y métodos para la producción de los mismos - Google Patents
Inhibidores de tyk2, usos y métodos para la producción de los mismosInfo
- Publication number
- AR111233A1 AR111233A1 ARP180100523A ARP180100523A AR111233A1 AR 111233 A1 AR111233 A1 AR 111233A1 AR P180100523 A ARP180100523 A AR P180100523A AR P180100523 A ARP180100523 A AR P180100523A AR 111233 A1 AR111233 A1 AR 111233A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- production
- same
- tyk2
- tyk2 inhibitors
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 229940123371 Tyrosine kinase 2 inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical group 0.000 abstract 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102000015774 TYK2 Kinase Human genes 0.000 abstract 1
- 108010010057 TYK2 Kinase Proteins 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente proporciona compuestos inhibidores de la tirosina quinasa 2 (Tyk2), formas sólidas y composiciones de los mismos, métodos para su producción y métodos de utilización de los mismos en el tratamiento de enfermedades mediadas por Tyk2. Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo, en donde cada uno de X, Y y Z es independientemente hidrógeno o deuterio.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762468688P | 2017-03-08 | 2017-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111233A1 true AR111233A1 (es) | 2019-06-19 |
Family
ID=63446346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100523A AR111233A1 (es) | 2017-03-08 | 2018-03-07 | Inhibidores de tyk2, usos y métodos para la producción de los mismos |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10336752B2 (es) |
| EP (2) | EP4338802A3 (es) |
| JP (3) | JP7160824B2 (es) |
| CN (1) | CN110582501B (es) |
| AR (1) | AR111233A1 (es) |
| AU (3) | AU2018230737B2 (es) |
| CA (1) | CA3055209A1 (es) |
| IL (1) | IL269036B2 (es) |
| TW (3) | TWI868528B (es) |
| WO (1) | WO2018165240A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016138352A1 (en) | 2015-02-27 | 2016-09-01 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| EP3344624B8 (en) | 2015-09-02 | 2023-11-29 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| CN110300590A (zh) | 2016-10-21 | 2019-10-01 | 林伯士拉克许米公司 | Tyk2抑制剂及其用途 |
| ES2994013T3 (en) | 2017-07-28 | 2025-01-15 | Takeda Pharmaceuticals Co | Tyk2 inhibitors and uses thereof |
| JP6557436B1 (ja) | 2018-03-12 | 2019-08-07 | アッヴィ・インコーポレイテッド | チロシンキナーゼ２媒介性シグナル伝達の阻害剤 |
| AU2019360941B2 (en) | 2018-10-15 | 2025-02-27 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
| CN113490664B (zh) * | 2018-10-22 | 2025-05-16 | 阿鲁米斯公司 | Tyk2抑制剂和其用途 |
| BR112021015616A2 (pt) * | 2019-02-07 | 2021-11-09 | Ventyx Biosciences Inc | Ligantes de pseudoquinase tyk2 |
| WO2020198379A1 (en) | 2019-03-26 | 2020-10-01 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
| JP2022537877A (ja) * | 2019-04-30 | 2022-08-31 | セルジーン コーポレイション | アプレミラストおよびｔｙｋ２阻害剤を含む併用療法 |
| US11357775B2 (en) | 2019-04-30 | 2022-06-14 | Celgene Corporation | Combination therapies comprising apremilast and Tyk2 inhibitors |
| UA129894C2 (uk) | 2019-11-08 | 2025-09-03 | Вентукс Біосціенціс, Інк. | Ліганди псевдокінази tyk2 |
| KR20240065283A (ko) * | 2021-09-23 | 2024-05-14 | 브리스톨-마이어스 스큅 컴퍼니 | Tyk2 억제제를 사용하여 탈모 장애를 치료하는 방법 |
| KR20240111312A (ko) | 2021-10-25 | 2024-07-16 | 카이메라 쎄라퓨틱스 인코포레이티드 | Tyk2 분해제 및 이의 용도 |
| EP4499645A1 (en) * | 2022-03-25 | 2025-02-05 | Takeda Pharmaceutical Company Limited | Solid forms of tyk2 inhibitors and methods of use |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4983612A (en) * | 1989-10-05 | 1991-01-08 | American Home Products Corporation | Antihypertensive benzopyran derivatives |
| DE4343923A1 (de) * | 1993-12-22 | 1995-06-29 | Basf Ag | Pyridin-2,3-dicarbonsäureimide, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses |
| ATE380031T1 (de) | 1999-12-10 | 2007-12-15 | Pfizer Prod Inc | Pyrrolo 2,3-d pyrimidinderivate enthaltende zusammensetzungen |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| CA2445395C (en) | 2001-04-27 | 2010-03-30 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent comprising the same as effective component |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| AU2003260399B2 (en) | 2002-08-14 | 2009-12-03 | Silence Therapeutics Gmbh | Use of protein kinase N beta |
| AU2003291021A1 (en) * | 2002-11-18 | 2004-06-15 | The Regents Of The University Of California | Arylpyridine compounds |
| BRPI0409063A (pt) | 2003-04-03 | 2006-03-28 | Semafore Pharmaceuticals Inc | pró medicamentos de inibidor de pi-3 cinase |
| KR101168441B1 (ko) | 2003-05-30 | 2012-07-25 | 게민 엑스 파마슈티컬스 캐나다 인코포레이티드 | 암 또는 바이러스 질환의 치료를 위한 삼복소환 화합물,조성물 및 방법 |
| WO2005007623A2 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| PT2612862T (pt) | 2004-05-13 | 2016-12-15 | Icos Corp | Quinazolinonas como inibidores de fosfatidilinositol 3-quinase delta humana |
| KR101278397B1 (ko) | 2005-01-19 | 2013-06-25 | 리겔 파마슈티칼스, 인크. | 2,4-피리미딘디아민 화합물의 전구약물 및 이의 용도 |
| NZ561609A (en) | 2005-05-12 | 2010-03-26 | Abbott Lab | 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| HRP20140975T1 (hr) | 2005-10-07 | 2014-11-21 | Exelixis, Inc. | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze |
| BR122021011787B1 (pt) | 2005-11-01 | 2022-01-25 | Impact Biomedicines, Inc | Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica |
| EP3838903B1 (en) | 2005-12-13 | 2023-11-22 | Incyte Holdings Corporation | Pyrrolo[2,3-d]pyrimidine derivative as janus kinase inhibitor |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| CL2007001165A1 (es) | 2006-04-26 | 2008-01-25 | Hoffmann La Roche | 2-(1h-indazol-4-il)-6-(4-metanosulfonil-piperazin-1-ilmetil)-4-morfolin-4-il-tieno[3,2-d]pirimidina; procedimiento de preparacion; composicion farmaceutica; proceso de preparacion de dicha composicion; kit farmaceutico; y uso para tratar enfermedades tales como cancer, desordenes inmunes y enfermedades cardiovasculares. |
| EA018573B1 (ru) | 2006-09-22 | 2013-09-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| EP3023422A1 (en) | 2007-03-12 | 2016-05-25 | YM BioSciences Australia Pty Ltd | Phenyl amino pyrimidine compounds and uses thereof |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| UA101493C2 (ru) | 2008-03-11 | 2013-04-10 | Инсайт Корпорейшн | Производные азетидина и циклобутана как ингибиторы jak |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US9273070B2 (en) * | 2010-12-22 | 2016-03-01 | Paul Knochel | Organozinc complexes and processes for making and using the same |
| WO2012097479A1 (en) * | 2011-01-21 | 2012-07-26 | Abbott Laboratories | Bicyclic inhibitors of anaphastic lymphoma kinase |
| US20130231340A1 (en) | 2012-03-02 | 2013-09-05 | Sareum Limited | Pharmaceutical compounds |
| BR112014029310A2 (pt) * | 2012-05-24 | 2018-06-26 | Cellzome Ltd | análogos da pirimidina heterocíclica como inibidores da tyk2 |
| CA2890981C (en) | 2012-11-08 | 2022-07-05 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses |
| EP2922841B8 (en) | 2012-11-08 | 2017-08-02 | Bristol-Myers Squibb Company | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| EP3080131B1 (en) | 2013-12-10 | 2018-10-10 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| AU2015222865B2 (en) | 2014-02-28 | 2019-06-20 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
| WO2016138352A1 (en) * | 2015-02-27 | 2016-09-01 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| EP3344624B8 (en) | 2015-09-02 | 2023-11-29 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| CN115448916A (zh) | 2016-10-14 | 2022-12-09 | 林伯士拉克许米公司 | Tyk2抑制剂及其用途 |
| CN110300590A (zh) | 2016-10-21 | 2019-10-01 | 林伯士拉克许米公司 | Tyk2抑制剂及其用途 |
-
2018
- 2018-03-07 TW TW111146722A patent/TWI868528B/zh active
- 2018-03-07 TW TW107107562A patent/TWI783978B/zh active
- 2018-03-07 TW TW113147070A patent/TW202515876A/zh unknown
- 2018-03-07 CN CN201880028375.5A patent/CN110582501B/zh active Active
- 2018-03-07 US US15/914,074 patent/US10336752B2/en active Active
- 2018-03-07 JP JP2019548301A patent/JP7160824B2/ja active Active
- 2018-03-07 IL IL269036A patent/IL269036B2/en unknown
- 2018-03-07 CA CA3055209A patent/CA3055209A1/en active Pending
- 2018-03-07 AU AU2018230737A patent/AU2018230737B2/en active Active
- 2018-03-07 EP EP24153142.5A patent/EP4338802A3/en active Pending
- 2018-03-07 WO PCT/US2018/021265 patent/WO2018165240A1/en not_active Ceased
- 2018-03-07 EP EP18764569.2A patent/EP3592746B1/en active Active
- 2018-03-07 AR ARP180100523A patent/AR111233A1/es unknown
-
2019
- 2019-05-21 US US16/417,901 patent/US11040967B2/en active Active
-
2022
- 2022-10-13 JP JP2022164799A patent/JP7535086B2/ja active Active
- 2022-10-19 AU AU2022256121A patent/AU2022256121A1/en not_active Abandoned
-
2024
- 2024-08-02 JP JP2024127741A patent/JP2024153877A/ja active Pending
- 2024-08-07 AU AU2024205575A patent/AU2024205575A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3592746A1 (en) | 2020-01-15 |
| TW201840559A (zh) | 2018-11-16 |
| JP7160824B2 (ja) | 2022-10-25 |
| TWI783978B (zh) | 2022-11-21 |
| WO2018165240A1 (en) | 2018-09-13 |
| US20180258086A1 (en) | 2018-09-13 |
| EP3592746B1 (en) | 2024-01-24 |
| AU2024205575A1 (en) | 2024-08-22 |
| JP2024153877A (ja) | 2024-10-29 |
| TWI868528B (zh) | 2025-01-01 |
| CN110582501B (zh) | 2022-09-23 |
| JP2020511438A (ja) | 2020-04-16 |
| IL269036A (en) | 2019-10-31 |
| CA3055209A1 (en) | 2018-09-13 |
| AU2018230737A1 (en) | 2019-09-19 |
| IL269036B2 (en) | 2023-03-01 |
| TW202515876A (zh) | 2025-04-16 |
| EP3592746A4 (en) | 2020-11-25 |
| AU2018230737B2 (en) | 2022-09-22 |
| EP4338802A2 (en) | 2024-03-20 |
| US11040967B2 (en) | 2021-06-22 |
| EP4338802A3 (en) | 2024-09-04 |
| JP2022185139A (ja) | 2022-12-13 |
| IL269036B (en) | 2022-11-01 |
| TW202321243A (zh) | 2023-06-01 |
| US10336752B2 (en) | 2019-07-02 |
| CN110582501A (zh) | 2019-12-17 |
| AU2022256121A1 (en) | 2022-11-17 |
| JP7535086B2 (ja) | 2024-08-15 |
| US20190337941A1 (en) | 2019-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR111233A1 (es) | Inhibidores de tyk2, usos y métodos para la producción de los mismos | |
| CO2021002651A2 (es) | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met | |
| CO2019007810A2 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| MX2022005610A (es) | Pirimidina-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos. | |
| UY36371A (es) | Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec | |
| DOP2016000281A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| EA201792116A1 (ru) | Ингибитор янус-киназы | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
| EA201692266A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| NI201600058A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| MX2016009230A (es) | Macrociclicos con grupos p2'heterociclicos como inhibidores del factor xia. | |
| EA201791576A1 (ru) | Ингибитор jak | |
| EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| CR20180307A (es) | Compuestos de imidazo[4,5-c] quinolin-2-ona y su uso en el tratamiento del cáncer | |
| CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| AR103680A1 (es) | Inhibidores selectivos de bace1 | |
| EA201692265A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| NZ752587A (en) | Lsd1 inhibitors and medical uses thereof | |
| DOP2020000072A (es) | Amidas de imidazopiridina sustituidas y su uso | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| SA519402103B1 (ar) | 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط | |
| CO2019002517A2 (es) | Inhibidores de dopamina–β–hidroxilasa | |
| MX2018002738A (es) | Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4. |